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A B S T R A C T
The first choice of antihypertensive therapy should include an agent with the best 
metabolic profile, usually an angiotensin-converting enzyme inhibitor (ACEI) or an-
giotensin receptor blocker (ARB), but additional agents should be used as needed to 
attain optimal blood pressure control, usually a diuretic or calcium-channel blocker 
(CCB) or both, whereas β-blockers should be used only if specially indicated for co-
morbidities, such as in cases of coexisting coronary disease or chronic heart failure.
It is now well established that a high blood pressure (BP) that can not be normalized 
by nonpharmacologic means (low salt diet, weight loss, exercise, smoking cessation), 
should be treated pharmacologically. The therapeutic target BP is still a moving target, 
as in the past it used to be ≤160/95 mmHg. However, nowadays most guidelines ac-
cept the epidemiologic target of ≤140/90 for the general population, whereas a lower 
target of ≤130/80 is desirable for high risk populations, such as diabetics or patients 
with chronic renal insufficiency. However, a really “normal” BP is now believed to be 
≤120/80 mmHg, because evidence from numerous observational studies (such as the 
Framingham Heart Study)1 and interventional long-term outcome trials indicates that 
even small increases in BP above this level are associated with a linear increase in risk 
of cardiovascular and cerebrovascular complications.
Whereas there is general agreement that lowering BP to target is the first and 
most important consideration, there is still ongoing debate as to what should be the 
first choice approach. There are six broad classes of antihypertensive drugs available 
today. The older agents are diuretics (including distal and loop diuretics), sympatholytic 
agents (including β-adrenergic blockers, α-adrenergic blockers and central sympathetic 
suppressants) and direct vasodilators (such as hydralazine and minoxidil); the newer 
classes are calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs).
The earlier clinical trials that produced incontrovertible evidence of benefit in 
terms of end organ protection from antihypertensive therapy, used mostly combina-
tions of thiazide diuretics with sympatholytics—mostly β-blockers. Interestingly, the 
results revealed significant decreases in rates of strokes, renal failure and heart failure, 
but only marginal and inconsistent decreases in coronary artery disease. A possible 
explanation for this was suggested by subsequent clinical studies that described the 
side-effects of these classes: the most important seems to be aggravation of insulin 
resistance (which is already a characteristic of untreated essential hypertension and 
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normal aging), resulting in hyperinsulinemia, hyperglycemia, 
dyslipidemia, i.e. components of what is now called the “car-
diometabolic syndrome.”2,3 Each one of these components, 
along with other metabolic disturbances that accompany 
diuretic therapy, such as hypokalemia, hyperuricemia and, not 
least, stimulation of the renin-angiotensin system, represent 
additional coronary risk factors that tend to partly offset the 
benefits of BP lowering.
By contrast, the newer classes of antihypertensive drugs 
are devoid of such adverse effects: The CCBs are metabolically 
neutral, whereas the ACEIs and ARBs are metabolically ben-
eficial, as they tend to restore insulin sensitivity and minimize 
metabolic aberrations. Indeed, in most comparative trials, 
the relative risk of new onset type 2 diabetes is diminished by 
about 18-20% with CCBs and 35-40% by ACEIs compared 
to thiazides.
So why is there still a debate regarding what should be the 
drug(s) of first choice? Two reasons: One is that the largest 
NIH-supported trial, the Antihypertensive and Lipid Lowering 
treatment to prevent Heart Attack Trial (ALLHAT),4,5 showed 
that patients on diuretic therapy had a significantly better 
BP control, lesser incidence of strokes and no difference in 
incidence of coronary events compared to patients on ACEI. 
Critics counteract that the study was poorly designed as it had 
a large proportion of black patients who respond to diuretics, 
but not to ACEIs, hence the ACEI group had significantly 
higher BPs throughout, hence more strokes and yet, not more 
coronary events, hinting at cardioprotection by the ACEI.
The second is the theory that drug-induced diabetes is 
somehow “benign” and should not be a deterrent, since pa-
tients who became diabetics during drug trials suffered a lot 
fewer cardiovascular events that patients who were already 
diabetics upon entering the trial. Critics counteract that these 
differences are quantitative, as they reflect a shorter duration 
of newly diabetic patients’ follow-up rather than qualitative 
differences in diabetic status; indeed new onset diabetes would 
be expected to produce complications at a later stage, beyond 
the specific trials’ follow-up period.
So common sense dictates that the first choice antihyper-
tensive should be one that offers the best metabolic profile 
(usually an ACEI or ARB), but additional agents should be 
used as needed to attain optimal BP control (usually a diuretic 
or CCB or both), whereas β-blockers should be used only if 
specially indicated for co-morbidities, such as in cases of co-
existing coronary disease or chronic heart failure.6-16
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